From Seekingalpha · SA Transcripts · · 40s
Xvivo Q3 Earnings Report
Xvivo Perfusion AB reports 32% organic growth in Q3 2026 earnings.
In brief
Xvivo Perfusion AB reports 32% organic growth in Q3 2026 earnings. Xvivo Perfusion AB achieved 32% organic growth in Q3 2026 with sales in line with prior half-year performance. Originally reported by Seekingalpha.
Q3 2026 Results
Xvivo Perfusion AB reported 32% organic growth in Q3 2026 with sales in line with the first half of the year.
Financial Performance
EBITDA remained strong, supporting healthy operating cash flow with total cash flow close to neutral for the fourth consecutive quarter.
Market Trends
Thoracic division continued strong performance across North America and Europe, supported by positive market trends from the end of last year.
At a glance
Xvivo Perfusion AB achieved 32% organic growth in Q3 2026 with sales in line with prior half-year performance.
